These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
73 related items for PubMed ID: 9578843
1. Gene therapy targeting cord blood-derived CD34+ cells from HIV-exposed infants: preclinical studies. Li X, Gervaix A, Kang D, Law P, Spector SA, Ho AD, Wong-Staal F. Gene Ther; 1998 Feb; 5(2):233-9. PubMed ID: 9578843 [Abstract] [Full Text] [Related]
2. Characterization of anti-CCR5 ribozyme-transduced CD34+ hematopoietic progenitor cells in vitro and in a SCID-hu mouse model in vivo. Bai J, Gorantla S, Banda N, Cagnon L, Rossi J, Akkina R. Mol Ther; 2000 Mar; 1(3):244-54. PubMed ID: 10933940 [Abstract] [Full Text] [Related]
3. Stem cells as vehicles for gene therapy: novel strategy for HIV infection. Ho AD, Li X, Lane TA, Yu M, Law P, Wong-Staal F. Stem Cells; 1995 Dec; 13 Suppl 3():100-5. PubMed ID: 8747996 [Abstract] [Full Text] [Related]
4. Increased gene transfer into human CD34+ progenitor cells using retroviral vectors produced by a canine packaging cell line. Bauer G, Sauter S, Ibanez C, Rice CR, Valdez P, Jolly D, Kohn DB. Biol Blood Marrow Transplant; 1998 Dec; 4(3):119-27. PubMed ID: 9923409 [Abstract] [Full Text] [Related]
5. Highly efficient gene transfer into preterm CD34 hematopoietic progenitor cells. Shields LE, Kiem HP, Andrews RG. Am J Obstet Gynecol; 2000 Sep; 183(3):732-7. PubMed ID: 10992201 [Abstract] [Full Text] [Related]
8. Growth factors increase retroviral transduction but decrease clonogenic potential of umbilical cord blood CD34+ cells. Corrias MV, Scuderi F, Pasino M, Biglino P, Bocca P, Marotta F, Figini E, Pistoia V, Mori PG. Haematologica; 1998 Jul; 83(7):580-6. PubMed ID: 9718861 [Abstract] [Full Text] [Related]
9. Evaluation of safety and efficacy of RNAi against HIV-1 in the human immune system (Rag-2(-/-)gammac(-/-)) mouse model. ter Brake O, Legrand N, von Eije KJ, Centlivre M, Spits H, Weijer K, Blom B, Berkhout B. Gene Ther; 2009 Jan; 16(1):148-53. PubMed ID: 18668146 [Abstract] [Full Text] [Related]
10. Clinical gene therapy research utilizing ribozymes: application to the treatment of HIV/AIDS. Ngok FK, Mitsuyasu RT, Macpherson JL, Boyd MP, Symonds GP, Amado RG. Methods Mol Biol; 2004 Jan; 252():581-98. PubMed ID: 15017082 [Abstract] [Full Text] [Related]
11. Complete knockdown of CCR5 by lentiviral vector-expressed siRNAs and protection of transgenic macrophages against HIV-1 infection. Anderson J, Akkina R. Gene Ther; 2007 Sep; 14(17):1287-97. PubMed ID: 17597795 [Abstract] [Full Text] [Related]
12. Transduction of CD34+ cells by a vesicular stomach virus protein G (VSV-G) pseudotyped HIV-1 vector. Stable gene expression in progeny cells, including dendritic cells. Li X, Mukai T, Young D, Frankel S, Law P, Wong-Staal F. J Hum Virol; 1998 Sep; 1(5):346-52. PubMed ID: 10195262 [Abstract] [Full Text] [Related]
13. Critical factors influencing stable transduction of human CD34(+) cells with HIV-1-derived lentiviral vectors. Haas DL, Case SS, Crooks GM, Kohn DB. Mol Ther; 2000 Jul; 2(1):71-80. PubMed ID: 10899830 [Abstract] [Full Text] [Related]
14. Sustained transgene expression by human cord blood derived CD34+ cells transduced with simian immunodeficiency virus agmTYO1-based vectors carrying the human coagulation factor VIII gene in NOD/SCID mice. Kikuchi J, Mimuro J, Ogata K, Tabata T, Ueda Y, Ishiwata A, Kimura K, Takano K, Madoiwa S, Mizukami H, Hanazono Y, Kume A, Hasegawa M, Ozawa K, Sakata Y. J Gene Med; 2004 Oct; 6(10):1049-60. PubMed ID: 15386735 [Abstract] [Full Text] [Related]
15. Ex vivo selection and expansion of cells based on expression of a mutated inosine monophosphate dehydrogenase 2 after HIV vector transduction: effects on lymphocytes, monocytes, and CD34+ stem cells. Yam P, Jensen M, Akkina R, Anderson J, Villacres MC, Wu J, Zaia JA, Yee JK. Mol Ther; 2006 Aug; 14(2):236-44. PubMed ID: 16647299 [Abstract] [Full Text] [Related]
16. Rapid analysis and efficient selection of human transduced primitive hematopoietic cells using the humanized S65T green fluorescent protein. Mazurier F, Moreau-Gaudry F, Maguer-Satta V, Salesse S, Pigeonnier-Lagarde V, Ged C, Belloc F, Lacombe F, Mahon FX, Reiffers J, de Verneuil H. Gene Ther; 1998 Apr; 5(4):556-62. PubMed ID: 9614582 [Abstract] [Full Text] [Related]
17. siRNAs, ribozymes and RNA decoys in modeling stem cell-based gene therapy for HIV/AIDS. Akkina R, Banerjea A, Bai J, Anderson J, Li MJ, Rossi J. Anticancer Res; 2003 Apr; 23(3A):1997-2005. PubMed ID: 12894572 [Abstract] [Full Text] [Related]
18. Long-term inhibition of HIV-1 infection in primary hematopoietic cells by lentiviral vector delivery of a triple combination of anti-HIV shRNA, anti-CCR5 ribozyme, and a nucleolar-localizing TAR decoy. Li MJ, Kim J, Li S, Zaia J, Yee JK, Anderson J, Akkina R, Rossi JJ. Mol Ther; 2005 Nov; 12(5):900-9. PubMed ID: 16115802 [Abstract] [Full Text] [Related]
19. Efficient gene transfer into human cord blood CD34+ cells and the CD34+CD38- subset using highly purified recombinant adeno-associated viral vector preparations that are free of helper virus and wild-type AAV. Nathwani AC, Hanawa H, Vandergriff J, Kelly P, Vanin EF, Nienhuis AW. Gene Ther; 2000 Feb; 7(3):183-95. PubMed ID: 10694794 [Abstract] [Full Text] [Related]
20. Efficiency of transgenic T cell generation from gene-marked cultured human CD34+ cord blood cells is determined by their maturity and the cytokines present in the culture medium. Verhasselt B, Naessens E, De Smedt M, Plum J. Gene Ther; 2000 May; 7(10):830-6. PubMed ID: 10845720 [Abstract] [Full Text] [Related] Page: [Next] [New Search]